News

Filter

Current filters:

Lantus

1 to 9 of 104 results

UPDATED: Sanofi chief executive Viehbacher allegedly issues letter to company board defending his position

UPDATED: Sanofi chief executive Viehbacher allegedly issues letter to company board defending his position

28-10-2014

Chris Viehbacher, chief executive of French drug major Sanofi, has urged the company’s board to clarify…

BoardroomFranceLantusPharmaceuticalSanofi

Physicians in South Korea and Taiwan expect good uptake of SGLT-2 inhibitors

Physicians in South Korea and Taiwan expect good uptake of SGLT-2 inhibitors

20-10-2014

Prescribers are enthusiastic about the emergence of SGLT2-2 inhibitors for type 2 diabetes, but payers…

AbasriaAsia-PacificDiabetesLantusPharmaceuticalResearch

Biosimilars one of the most promising segments of European pharma industry, says KuickResearch

Biosimilars one of the most promising segments of European pharma industry, says KuickResearch

09-10-2014

Biosimilars are one of the most promising segments of the European pharma industry, according to a report…

BiosimilarsEuropeLantusMarkets & MarketingPharmacology

Mylan starts Ph III trials for generics of Advair Diskus and insulin analog to Lantus

16-09-2014

US generic drugs major Mylan says it is initiating Phase III clinical trials for its generic version…

Advair DiskusDiabetesGenericsGlaxoSmithKlineLantusMylanResearchRespiratory and PulmonarySanofi

EU approval for Boehringer and Lilly’s insulin glargine biosimilar

EU approval for Boehringer and Lilly’s insulin glargine biosimilar

10-09-2014

The European Commission granted marketing authorization for US drug major Eli Lilly and family-owned…

AbasriaBasaglarBiosimilarsBoehringer IngelheimDiabetesEli LillyEuropeInsulinLantusPharmaceuticalRegulationSanofi

Lilly's peglispro shows HbA1c superiority against Lantus in Ph III trials

Lilly's peglispro shows HbA1c superiority against Lantus in Ph III trials

04-09-2014

US pharma major Eli Lilly has released additional clinical data showing superiority for its diabetes…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

India’s Lupin launches insulin glargine analogue Basugine

11-08-2014

Indian generic drugmaker Lupin has entered into a strategic distribution agreement with LG Life Sciences…

BasugineBiosimilarsDiabetesGenericsIndiaLantusLG Life SciencesLupinMarkets & MarketingPeptide hormonesRecombinant proteinsSanofi

1 to 9 of 104 results

COMPANY SPOTLIGHT

Menarini

Back to top